评估与卡铂和紫杉醇辅助化疗联合放射治疗晚期子宫内膜癌相关的无病生存期 (DFS) 和总生存期 (OS)。这是一项针对在单一机构接受治疗的 III 期或 IV 期子宫内膜癌成年女性的队列研究，2002 年 4 月至 2017 年 10 月期间。记录肿瘤和治疗特征。治疗包括每 3 周静脉注射 4 个周期的紫杉醇和卡铂，然后进行骨盆外照射放射治疗 (45-50 Gy)，以及另外 2 个周期的化疗。一组患者从 2002 年至 2006 年前瞻性入组，另一组患者从 2007 年至 2017 年前瞻性入组，并进行回顾性分析。本研究的主要终点是使用 Cox 回归模型计算的 DFS 和 OS 率。纳入了 82 名中位年龄为 66.5 岁（范围为 35-83 岁）的患者。中位随访时间为 46 个月（范围：9-196 个月）。大多数患者患有 IIIC 期疾病（62.2%）和浆液性癌组织学（46.3%）。中位 OS 为 146 个月，中位 DFS 为 71 个月。 5 年 OS 和 DFS 分别为 64.9% 和 55.7%。年龄 >60 岁亚组发生 DFS 事件或死亡的风险显着较高。组织学亚型、阳性淋巴结位置和癌症分期（IIIa 期与更高分期）与较高的复发或死亡风险无关。长期随访和更大的人群证实，放化疗三明治法对患者产生良好的结果患有高危子宫内膜癌。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

To evaluate disease-free survival (DFS) and overall survival (OS) associated with adjuvant carboplatin and paclitaxel chemotherapy interposed with radiation for advanced endometrial cancer.This is a cohort study of adult women with stage III or IV endometrial cancer treated at a single institution, between April 2002 and October 2017. Tumor and treatment characteristics were recorded. Treatment consisted of 4 cycles of intravenous paclitaxel and carboplatin every 3 weeks, followed by external beam radiotherapy to the pelvis (45-50 Gy), and another 2 cycles of chemotherapy. One cohort of patients were prospectively enrolled from 2002 through 2006 and an additional cohort from 2007 to 2017, which was retrospectively analyzed. Primary endpoints for this study were DFS and OS rates which were calculated using Cox regression models.Eighty-two patients with a median age of 66.5 years (range, 35-83 years) were included. Median follow-up was 46 months (range, 9-196 months). Most patients had stage IIIC disease (62.2%) and serous carcinoma histology (46.3%). Median OS was 146 months and median DFS was 71 months. A 5-year OS and DFS were 64.9% and 55.7%, respectively. Age >60 years subgroup was at a significantly higher risk of DFS event or death. Histological subtype, location of positive nodes, and cancer stage (IIIa vs. higher stage) did not correlate to a higher risk of recurrence or death.Long term follow-up and a larger population confirm that the chemoradiotherapy sandwich method yields favorable outcomes in patients with high-risk endometrial cancer.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.